These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Biotech IPOs--flop or pop? Jacobs T Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641 [No Abstract] [Full Text] [Related]
7. Chasing biotech, state by state--winners and losers. Wilan KH Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143 [No Abstract] [Full Text] [Related]
8. Stock options could no longer be the carrot. Lawrence S Nat Biotechnol; 2005 Feb; 23(2):157. PubMed ID: 15696132 [No Abstract] [Full Text] [Related]
9. Biotech financing retrenches in Q2. Lawrence S Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116 [No Abstract] [Full Text] [Related]
10. Managing your compensation expectations in today's environment: a third look. Radford J Nat Biotechnol; 2005 Dec; 23(12):1569-70. PubMed ID: 16333298 [TBL] [Abstract][Full Text] [Related]
11. The stampede to convertibles. Jacobs T Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195 [No Abstract] [Full Text] [Related]
13. Biotechnology financing dilemmas and the role of special purpose entities. Schiff L; Murray F Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945 [No Abstract] [Full Text] [Related]
14. US venture capital for biotechnology. Dibner MD; Trull M; Howell M Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144 [No Abstract] [Full Text] [Related]
18. Companies jostle for access to public markets. Bouchie A Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309 [No Abstract] [Full Text] [Related]
19. IPOs: the narrow window closes? Lawrence S Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641 [No Abstract] [Full Text] [Related]
20. Let the chips fall where they may. Jacobs T Nat Biotechnol; 2003 Feb; 21(2):129. PubMed ID: 12560829 [No Abstract] [Full Text] [Related] [Next] [New Search]